Background: Urinary tract infections (UTIs) are common in renal patients, presenting significant clinical challenges due to impaired immune function and frequent medical interventions. The growing prevalence of antimicrobial resistance (AMR) in uropathogens complicates the treatment of these infections, posing a serious health risk in renal disease populations, including those with chronic kidney disease (CKD), dialysis-dependent patients, and renal transplant recipients. AMR in uropathogens such as Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecalis is an emerging concern, leading to treatment failures and increased morbidity. Objective: This study investigates the prevalence of AMR in uropathogens causing UTIs in renal patients, identifies risk factors contributing to resistance, and evaluates alternative treatment strategies in the face of increasing antimicrobial resistance. Methods: A prospective cohort study was conducted involving 500 renal patients diagnosed with UTIs at a tertiary care center. Urine samples were cultured, and antimicrobial susceptibility testing was performed to identify resistance patterns. Patient demographics, comorbidities, renal function status, and use of medical devices were recorded. Statistical analysis was performed to determine the association of AMR with clinical factors such as stage of CKD, prior antibiotic use, and presence of indwelling catheters. Results: Over 45% of uropathogens were resistant to common first-line antibiotics, with E. coli exhibiting the highest resistance. Meropenem and fosfomycin showed the most favorable outcomes in resistant infections, with success rates of 92.3% and 87.5%, respectively. Resistance was significantly higher in patients with advanced CKD and those with catheter use. These results underscore the urgency of developing alternative strategies for managing UTIs in renal patients. Conclusion: Antimicrobial resistance is a major challenge in managing UTIs in renal patients. The findings highlight the need for targeted antimicrobial stewardship, surveillance of resistance patterns, and the incorporation of alternative therapies, such as meropenem and fosfomycin, to combat multidrug-resistant infections. Further research is necessary to optimize treatment regimens and improve clinical outcomes for this high-risk population.